Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
Arch. argent. pediatr ; 120(1): e49-e53, feb 2022. tab, ilus
Article in Spanish | LILACS, BINACIS | ID: biblio-1353830

ABSTRACT

El síndrome de lisis tumoral es una complicación potencialmente letal y constituye, junto con las infecciones, la emergencia oncológica más frecuente. En pediatría, este cuadro puede ser secundario a enfermedades neoplásicas, y los corticoides son un factor desencadenante. En este trabajo se presenta el caso de una paciente adolescente, sin neoplasias conocidas o evidentes, que desarrolló un síndrome de lisis tumoral luego de la administración de corticoides por sospecha de una infección respiratoria. Se discute la forma de presentación y los diagnósticos diferenciales del cuadro clínico inicial. Se hace especial foco en la administración de corticoides en cuadros clínicos en los que no existe evidencia científica que respalde fuertemente su indicación. El uso de corticosteroides sistémicos en infecciones respiratorias agudas debe ser evaluado en el contexto clínico y solo debe indicarse en situaciones con probada efectividad.


Tumor lysis syndrome is a potentially lethal complication and constitutes with infections the most frequent oncological emergency. In children, this condition can be secondary to neoplastic diseases, with corticosteroids being a triggering factor. This paper presents the case of an adolescent patient, without known or obvious neoplasms, who developed a tumor lysis syndrome after the administration of corticosteroids due to suspected respiratory infection.The clinical presentation and differential diagnoses are discussed. Special focus is placed on the administration of corticosteroids in clinical conditions with weak scientific evidence. The use of systemic corticosteroids in acute respiratory infections should be evaluated in the clinical context and only indicated in situations with proven effectiveness.


Subject(s)
Humans , Female , Adolescent , Tumor Lysis Syndrome/diagnosis , Tumor Lysis Syndrome/etiology , Adrenal Cortex Hormones/adverse effects
2.
Arch Argent Pediatr ; 120(1): e49-e53, 2022 02.
Article in Spanish | MEDLINE | ID: mdl-35068131

ABSTRACT

Tumor lysis syndrome is a potentially lethal complication and constitutes with infections the most frequent oncological emergency. In children, this condition can be secondary to neoplastic diseases, with corticosteroids being a triggering factor. This paper presents the case of an adolescent patient, without known or obvious neoplasms, who developed a tumor lysis syndrome after the administration of corticosteroids due to suspected respiratory infection. The clinical presentation and differential diagnoses are discussed. Special focus is placed on the administration of corticosteroids in clinical conditions with weak scientific evidence. The use of systemic corticosteroids in acute respiratory infections should be evaluated in the clinical context and only indicated in situations with proven effectiveness.


El síndrome de lisis tumoral es una complicación potencialmente letal y constituye, junto con las infecciones, la emergencia oncológica más frecuente. En pediatría, este cuadro puede ser secundario a enfermedades neoplásicas, y los corticoides son un factor desencadenante. En este trabajo se presenta el caso de una paciente adolescente, sin neoplasias conocidas o evidentes, que desarrolló un síndrome de lisis tumoral luego de la administración de corticoides por sospecha de una infección respiratoria. Se discute la forma de presentación y los diagnósticos diferenciales del cuadro clínico inicial. Se hace especial foco en la administración de corticoides en cuadros clínicos en los que no existe evidencia científica que respalde fuertemente su indicación. El uso de corticosteroides sistémicos en infecciones respiratorias agudas debe ser evaluado en el contexto clínico y solo debe indicarse en situaciones con probada efectividad.


Subject(s)
Tumor Lysis Syndrome , Adolescent , Adrenal Cortex Hormones/adverse effects , Child , Humans , Tumor Lysis Syndrome/diagnosis , Tumor Lysis Syndrome/etiology
3.
REVISA (Online) ; 10(1): 77-93, 2021.
Article in Portuguese | LILACS | ID: biblio-1177135

ABSTRACT

Objetivo: analisar a produção científica sobre a lesão renal aguda causada pela síndrome da Lise tumoral no paciente internado em unidade de terapia intensiva, bem como o conhecimento do enfermeiro sobre tal patologia. Método: Trata-se de um artigo de revisão integrativa realizado através da leitura de 30 artigos científicos retirados da Biblioteca Virtual de Saúde. Resultados: Identificouse a ocorrência da lesão renal aguda e síndrome de lise tumoral através das alterações metabólicas e hemodinâmicas nos pacientes internados na unidade de terapia intensiva e observou-se que não há publicações com relatos do enfermeiro sobre o conhecimento desta patologia. Conclusão: Apesar dos estudos atuais e a busca constante pelo conhecimento, sabe-se que a lesão renal aguda e Síndrome de Lise Tumoral é uma emergência oncológica com alta taxa de morbidade, onde a principal estratégia para melhorar a evolução de pacientes é estabelecer medidas profiláticas e o tratamento adequado com urgência. Deve existir uma análise contínua do enfermeiro, bem como de toda equipe, estratificação dos riscos e elaboração de protocolos de controles hidroeletrolíticos e laboratoriais para estabilização hemodinâmica do paciente oncológico na unidade de terapia intensiva.


Objective: to analyze the scientific production on acute kidney injury caused by tumor lysis syndrome in patients admitted to the intensive care unit, as well as the nurses' knowledge about such pathology. Method: This is an integrative review article carried out by reading 30 scientific articles taken from the Virtual Health Library. Results: The occurrence of acute kidney injury and tumor lysis syndrome was identified through metabolic and hemodynamic changes in patients admitted to the intensive care unit and it was observed that there are no publications with nurses' reports on the knowledge of this pathology. Conclusion: Despite current studies and the constant search for knowledge, it is known that acute kidney injury and Tumor Lysis Syndrome is an oncological emergency with a high morbidity rate, where the main strategy to improve the evolution of patients is to establish prophylactic measures and appropriate urgent treatment. There must be a continuous analysis of the nurse, as well as the entire team, risk stratification and elaboration of hydroelectrolytic and laboratory control protocols for hemodynamic stabilization of the cancer patient in the intensive care unit.


Objetivo: analizar la producción científica sobre la lesión renal aguda por síndrome de lisis tumoral en pacientes ingresados en la unidad de cuidados intensivos, así como el conocimiento de los enfermeros sobre dicha patología. Método: Se trata de un artículo de revisión integradora realizada mediante la lectura de 30 artículos científicos extraídos de la Biblioteca Virtual en Salud. Resultados: Se identificó la ocurrencia de daño renal agudo y síndrome de lisis tumoral a través de cambios metabólicos y hemodinámicos en pacientes ingresó en la unidad de cuidados intensivos y se observó que no existen publicaciones con informes de enfermeras sobre el conocimiento de esta patología. Conclusión: a pesar de los estudios actuales y la búsqueda constante de conocimiento, se sabe que la lesión renal aguda y el síndrome de lisis tumoral es una emergencia oncológica con una alta morbilidad, donde la principal estrategia para mejorar la evolución de los pacientes es establecer medidas profilácticas. y tratamiento urgente apropiado. Se debe realizar un análisis continuo de la enfermera, así como de todo el equipo, estratificación de riesgo y elaboración de protocolos de control hidroelectrolítico y de laboratorio para la estabilización hemodinámica del paciente oncológico en la unidad de cuidados intensivos.


Subject(s)
Humans , Tumor Lysis Syndrome/complications , Health Knowledge, Attitudes, Practice , Acute Kidney Injury/etiology , Intensive Care Units , Nurse Practitioners , Tumor Lysis Syndrome/etiology
4.
In. Manzanares Castro, William; Aramendi Epstein, Ignacio; Pico, José Luis do. Disionías en el paciente grave: historias clínicas comentadas. Montevideo, Cuadrado, 2021. p.357-370, tab.
Monography in Spanish | LILACS, UY-BNMED, BNUY | ID: biblio-1344746
5.
Arch Argent Pediatr ; 118(2): S59-S63, 2020 04.
Article in Spanish | MEDLINE | ID: mdl-32199069

ABSTRACT

The tumor lysis syndrome represents a potentially lethal complication caused by the massive release of nucleic acids, potassium and phosphate into the circulation as a result of the lysis of neoplastic cells, which are characterized by a rapid proliferation capacity and high sensitivity to drugs. This may occur spontaneously prior to the start of treatment, becoming worse after the initiation of chemotherapy. It presents a high mortality; its prevention continues being the most important therapeutic measure. The clinical picture is characterized by the existence of hydroelectrolytic metabolism disorders, in particular hyperkalemia, hyperphosphatemia and hyperuricemia and by the appearance of an acute renal lesion. Adequate therapeutic intervention involves intravenous hydration and measures to prevent or correct metabolic alterations. This article proposes guidelines to follow both in the diagnostic stage and in the treatment of this complication.


El síndrome de lisis tumoral representa una complicación potencialmente letal provocada por la liberación masiva de ácidos nucleicos, potasio y fosfato hacia la circulación como resultado de la lisis de células neoplásicas, las cuales se caracterizan por una rápida capacidad de proliferación y alta sensibilidad a fármacos. Esto puede ocurrir de forma espontánea antes del inicio del tratamiento y agravarse luego de haberse iniciado la quimioterapia. Presenta una alta mortalidad. Su prevención continúa siendo la medida terapéutica más importante. El cuadro clínico se caracteriza por la existencia de trastornos del metabolismo hidroelectrolítico, en particular, hipercalemia, hiperfosfatemia e hiperuricemia y por la aparición de una lesión renal aguda. Una adecuada intervención terapéutica implica hidratación intravenosa y medidas para prevenir o corregir las alteraciones metabólicas. En este artículo, se proponen lineamientos para seguir tanto en la etapa diagnóstica como en el tratamiento de esta complicación.


Subject(s)
Tumor Lysis Syndrome/diagnosis , Tumor Lysis Syndrome/therapy , Combined Modality Therapy , Humans , Risk Factors , Tumor Lysis Syndrome/etiology , Tumor Lysis Syndrome/physiopathology
6.
Medicina (B Aires) ; 79(6): 516-519, 2019.
Article in Spanish | MEDLINE | ID: mdl-31829957

ABSTRACT

Tumor lysis syndrome (SLT) is a rare and potentially fatal entity. It represents an oncological emergency. It can be diagnosed by its clinical presentation and also by laboratory results. In most cases it is presented as a complication of the chemotherapeutic treatment of oncohematological diseases with large tumor mass. Less frequently, a syndrome of spontaneous tumor lysis has been described, or secondary to the use of corticosteroids, hydroxyurea and radiotherapy. In its most severe forms it may require hospitalization in intensive care units and invasive therapeutic measures such as hemodialysis. We report four cases of SLT with unusual presentation characteristics admitted to our Medical Research Institute.


El síndrome de lisis tumoral (SLT) es una entidad poco frecuente y potencialmente fatal. Representa una emergencia oncológica. Puede diagnosticarse por su forma de presentación clínica y también por los resultados de laboratorio. En la mayoría de los casos se presenta como complicación del tratamiento quimioterapéutico de enfermedades oncohematológicas con gran masa tumoral. Con menor frecuencia se ha descrito un síndrome de lisis tumoral espontáneo, o secundario al uso de corticoides, hidroxiurea y radioterapia. En sus formas más graves puede requerir internación en unidades de terapia intensiva y medidas terapéuticas invasivas como la hemodiálisis. Comunicamos cuatro casos de SLT con características de presentación inusual internados en nuestro Instituto de Investigaciones Médicas.


Subject(s)
Tumor Lysis Syndrome/pathology , Adult , Aged , Antineoplastic Agents/adverse effects , Fatal Outcome , Female , Humans , Male , Middle Aged , Renal Insufficiency/etiology , Renal Insufficiency/physiopathology , Tumor Lysis Syndrome/etiology , Tumor Lysis Syndrome/physiopathology
7.
Medicina (B.Aires) ; Medicina (B.Aires);79(6): 516-519, dic. 2019. tab
Article in Spanish | LILACS | ID: biblio-1056763

ABSTRACT

El síndrome de lisis tumoral (SLT) es una entidad poco frecuente y potencialmente fatal. Representa una emergencia oncológica. Puede diagnosticarse por su forma de presentación clínica y también por los resultados de laboratorio. En la mayoría de los casos se presenta como complicación del tratamiento quimioterapéutico de enfermedades oncohematológicas con gran masa tumoral. Con menor frecuencia se ha descrito un síndrome de lisis tumoral espontáneo, o secundario al uso de corticoides, hidroxiurea y radioterapia. En sus formas más graves puede requerir internación en unidades de terapia intensiva y medidas terapéuticas invasivas como la hemodiálisis. Comunicamos cuatro casos de SLT con características de presentación inusual internados en nuestro Instituto de Investigaciones Médicas.


Tumor lysis syndrome (SLT) is a rare and potentially fatal entity. It represents an oncological emergency. It can be diagnosed by its clinical presentation and also by laboratory results. In most cases it is presented as a complication of the chemotherapeutic treatment of oncohematological diseases with large tumor mass. Less frequently, a syndrome of spontaneous tumor lysis has been described, or secondary to the use of corticosteroids, hydroxyurea and radiotherapy. In its most severe forms it may require hospitalization in intensive care units and invasive therapeutic measures such as hemodialysis. We report four cases of SLT with unusual presentation characteristics admitted to our Medical Research Institute.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Tumor Lysis Syndrome/pathology , Tumor Lysis Syndrome/etiology , Tumor Lysis Syndrome/physiopathology , Fatal Outcome , Renal Insufficiency/etiology , Renal Insufficiency/physiopathology , Antineoplastic Agents/adverse effects
8.
J Biol Inorg Chem ; 24(4): 547-562, 2019 06.
Article in English | MEDLINE | ID: mdl-31030325

ABSTRACT

Massive lysis of tumor mass in cancer patients under chemotherapy regimens generates high levels of uric acid, leading to what is known as tumor lysis syndrome (TLS). Rasburicase, a recombinant urate oxidase, converts urate to allantoin, which is readily excreted by the kidneys. Even though there is a high production of allantoin from urate in cancer patients following rasburicase treatment, there are no studies on how allantoin excess could interfere with chemotherapy. We have evaluated allantoin interference with cisplatin efficiency on the lung cancer cell line H460 in vitro. The cells were treated with cisplatin (33 µM), with or without allantoin, for 48 h, in the presence or absence of UV light, and N-acetyl-L-cysteine (NAC) for 24 h. Cell viability, cell cycle, ROS production, apoptosis and immunoblot assays were performed. We showed that allantoin reduced the apoptosis induced by cisplatin in the H460 cell line. However, the activity of carboplatin and oxaliplatin, betulinic acid, TIBA, UV and H2O2 was not affected by allantoin. NMR spectroscopy showed that allantoin reduces cisplatin activity through direct interaction with cisplatin.


Subject(s)
Allantoin/pharmacology , Cell Death/drug effects , Cisplatin/adverse effects , Tumor Lysis Syndrome/drug therapy , Tumor Lysis Syndrome/etiology , Apoptosis/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Humans , Hydrogen Peroxide/pharmacology , Tumor Lysis Syndrome/pathology
12.
Arch Argent Pediatr ; 110(6): e118-22, 2012 Dec.
Article in Spanish | MEDLINE | ID: mdl-23224315

ABSTRACT

An adolescent with acute lymphoblastic leukemia developed an early and severe tumor lysis syndrome with acute kidney injury after a low and single dose of steroids. Renal dysfunction was attributed primarily to phosphate nephropathy with nephrocalcinosis due to extreme elevations of phosphate in blood. Urinary alkalinization probably contributed to this development. We used peritoneal dialysis with resolution of nephrocalcinosis and normalization of creatinine clearance.


Subject(s)
Acute Kidney Injury/etiology , Acute Kidney Injury/therapy , Peritoneal Dialysis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Tumor Lysis Syndrome/complications , Acute Kidney Injury/urine , Adolescent , Alkalies/urine , Child , Female , Glucocorticoids/adverse effects , Humans , Methylprednisolone/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Tumor Lysis Syndrome/etiology
13.
Arch. argent. pediatr ; 110(6): e118-e122, dic. 2012. ilus, tab
Article in Spanish | LILACS | ID: lil-662135

ABSTRACT

Una adolescente con leucemia linfoblástica aguda desarrolló un síndrome de lisis tumoral precoz y grave con lesión renal aguda luego de una dosis única y baja de esteroides. La disfunción renal se atribuyó primariamente a una nefropatía por fosfato con nefrocalcinosis debido a elevaciones extremas de este componente en sangre. La alcalinización urinaria probablemente contribuyó a su patogenia. Se utilizó diálisis peritoneal con resolución de la nefrocalcinosis y normalización de la depuración de creatinina.


An adolescent with acute lymphoblastic leukemia developed an early and severe tumor lysis syndrome with acute kidney injury after a low and single dose of steroids. Renal dysfunction was attributed primarily to phosphate nephropathy with nephrocalcinosis due to extreme elevations of phosphate in blood. Urinary alkalinization probably contributed to this development. We used peritoneal dialysis with resolution of nephrocalcinosis and normalization of creatinine clearance.


Subject(s)
Adolescent , Child , Female , Humans , Acute Kidney Injury/etiology , Acute Kidney Injury/therapy , Peritoneal Dialysis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Tumor Lysis Syndrome/complications , Acute Kidney Injury/urine , Alkalies/urine , Glucocorticoids/adverse effects , Methylprednisolone/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Tumor Lysis Syndrome/etiology
14.
Arch. argent. pediatr ; 110(6): e118-e122, dic. 2012. ilus, tab
Article in Spanish | BINACIS | ID: bin-129068

ABSTRACT

Una adolescente con leucemia linfoblástica aguda desarrolló un síndrome de lisis tumoral precoz y grave con lesión renal aguda luego de una dosis única y baja de esteroides. La disfunción renal se atribuyó primariamente a una nefropatía por fosfato con nefrocalcinosis debido a elevaciones extremas de este componente en sangre. La alcalinización urinaria probablemente contribuyó a su patogenia. Se utilizó diálisis peritoneal con resolución de la nefrocalcinosis y normalización de la depuración de creatinina.(AU)


An adolescent with acute lymphoblastic leukemia developed an early and severe tumor lysis syndrome with acute kidney injury after a low and single dose of steroids. Renal dysfunction was attributed primarily to phosphate nephropathy with nephrocalcinosis due to extreme elevations of phosphate in blood. Urinary alkalinization probably contributed to this development. We used peritoneal dialysis with resolution of nephrocalcinosis and normalization of creatinine clearance.(AU)


Subject(s)
Adolescent , Child , Female , Humans , Acute Kidney Injury/etiology , Acute Kidney Injury/therapy , Peritoneal Dialysis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Tumor Lysis Syndrome/complications , Acute Kidney Injury/urine , Alkalies/urine , Glucocorticoids/adverse effects , Methylprednisolone/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Tumor Lysis Syndrome/etiology
15.
Medicina (B Aires) ; 71(2): 158-60, 2011.
Article in Spanish | MEDLINE | ID: mdl-21550933

ABSTRACT

The tumor lysis syndrome (TLS) is a metabolic disorder resulting from a massive tumor breakdown. It is characterized by hyperuricemia, hyperphosphatemia, hypocalcemia and hyperkalemia and predisposes to acute renal failure. TLS usually occurs after the initiation of cytotoxic therapy and is more frequent in the case of neoplasias with a high proliferative rate or that are highly chemo-sensitive. We report the case of a man with a recurrent kidney cancer who presented with a TLS and acute renal failure after initiation of sunitinib.


Subject(s)
Angiogenesis Inhibitors/adverse effects , Carcinoma, Renal Cell/drug therapy , Indoles/adverse effects , Kidney Neoplasms/drug therapy , Pyrroles/adverse effects , Tumor Lysis Syndrome/etiology , Fatal Outcome , Humans , Male , Middle Aged , Sunitinib
16.
Medicina (B.Aires) ; Medicina (B.Aires);71(2): 158-160, mar.-abr. 2011. tab
Article in Spanish | LILACS | ID: lil-633836

ABSTRACT

El síndrome de lisis tumoral (SLT) es un trastorno metabólico que ocurre como consecuencia de una destrucción celular masiva. Se caracteriza por la presencia de hiperuricemia, hiperfosfatemia, hipocalcemia e hiperkalemia, y predispone al desarrollo de insuficiencia renal aguda. En la mayoría de los casos el SLT ocurre luego de instaurarse un tratamiento antitumoral y es más frecuente en tumores de alto grado de malignidad y alta sensibilidad a la quimioterapia. Presentamos el caso de un paciente con diagnóstico de cáncer de riñón recidivado que presenta un SLT e insuficiencia renal aguda luego de iniciar tratamiento con sunitinib.


The tumor mor lysis syndrome (TLS) is a metabolic disorder resulting from a massive tumor breakdown. It is characterized by hyperuricemia, hyperphosphatemia, hypocalcemia and hyperkalemia and predisposes to acute renal failure. TLS usually occurs after the initiation of cytotoxic therapy and is more frequent in the case of neoplasias with a high proliferative rate or that are highly chemo-sensitive. We report the case of a man with a recurrent kidney cancer who presented with a TLS and acute renal failure after initiation of sunitinib.


Subject(s)
Humans , Male , Middle Aged , Angiogenesis Inhibitors/adverse effects , Carcinoma, Renal Cell/drug therapy , Indoles/adverse effects , Kidney Neoplasms/drug therapy , Pyrroles/adverse effects , Tumor Lysis Syndrome/etiology , Fatal Outcome
17.
Rev Med Chil ; 134(6): 763-6, 2006 Jun.
Article in Spanish | MEDLINE | ID: mdl-17130952

ABSTRACT

The treatment of AL amyloidosis was not successful until the advent of myeloablative chemotherapy consisting of high-dose intravenous melphalan followed by autologous peripheral blood stem cell transplantation. This new treatment has achieved better survival rates and, remarkably, it has obtained complete remission. Among patients with renal involvement, achievement of a complete hematological response was associated with a 50% reduction in proteinuria and stable creatinine clearance in more than 2/3 of patients. Despite of these excellent results, this new therapy is associated with significant toxicity, including the development of acute renal failure due to white blood cell lysis syndrome. We report a 59 year-old female with a nephrotic syndrome due to primary amyloidosis successfully treated autologous stem cell transplantation who developed acute renal failure caused by white blood cell lysis syndrome. The patient required treatment with granulocytic colony stimulating factor and intermittent hemofiltration and was discharged 23 days after melphalan administration with a satisfactory renal function and white blood cell count. After one year of follow up, she maintains a good glomerular filtration rate, a proteinuria of less than, 1 g/day and normal hematological values.


Subject(s)
Amyloidosis/complications , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Melphalan/adverse effects , Myeloablative Agonists/adverse effects , Peripheral Blood Stem Cell Transplantation/adverse effects , Tumor Lysis Syndrome/etiology , Acute Kidney Injury/chemically induced , Amyloidosis/blood , Amyloidosis/therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Female , Humans , Melphalan/blood , Melphalan/therapeutic use , Middle Aged , Myeloablative Agonists/therapeutic use , Transplantation, Autologous , Tumor Lysis Syndrome/blood , Tumor Lysis Syndrome/drug therapy
18.
Rev. méd. Chile ; 134(6): 763-766, jun. 2006. tab
Article in Spanish | LILACS | ID: lil-434625

ABSTRACT

The treatment of AL amyloidosis was not successful until the advent of myeloablative chemotherapy consisting of high-dose intravenous melphalan followed by autologous peripheral blood stem cell transplantation. This new treatment has achieved better survival rates and, remarkably, it has obtained complete remission. Among patients with renal involvement, achievement of a complete hematological response was associated with a 50% reduction in proteinuria and stable creatinine clearance in more than 2/3 of patients. Despite of these excellent results, this new therapy is associated with significant toxicity, including the development of acute renal failure due to white blood cell lysis syndrome. We report a 59 year-old female with a nephrotic syndrome due to primary amyloidosis successfully treated autologous stem cell transplantation who developed acute renal failure caused by white blood cell lysis syndrome. The patient required treatment with granulocytic colony stimulating factor and intermittent hemofiltration and was discharged 23 days after melphalan administration with a satisfactory renal function and white blood cell count. After one year of follow up, she maintains a good glomerular filtration rate, a proteinuria of less than, 1 g/day and normal hematological values.


Subject(s)
Female , Humans , Middle Aged , Amyloidosis/complications , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Melphalan/adverse effects , Myeloablative Agonists/adverse effects , Peripheral Blood Stem Cell Transplantation/adverse effects , Tumor Lysis Syndrome/etiology , Acute Kidney Injury , Amyloidosis/blood , Amyloidosis/therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Melphalan/blood , Melphalan/therapeutic use , Myeloablative Agonists/therapeutic use , Transplantation, Autologous , Tumor Lysis Syndrome/blood , Tumor Lysis Syndrome/drug therapy
19.
Rev. chil. pediatr ; 72(6): 524-527, nov.-dic. 2001. graf
Article in Spanish | LILACS | ID: lil-313234

ABSTRACT

Se presenta el caso de una escolar de 10 años de edad tratada con quimioterapia a causa de una leucemia linfoblástica aguda, que a pesar de las medidas preventivas presenta hiperuricemia, hiperfosfemia, hipercalemia y disminución de la diuresis, por lo que se diagnostica síndrome de lisis tumoral y se inicia tratamiento conservador y luego, por falta de respuesta, se realiza peritoneo diálisis, eligiéndose esta modalidad por inestabilidad hemodinámica y trastornos de la coagulación, lo que contraindicaba la hemodiálisis. Al tercer día mejoran los valores plasmáticos del ácido úrico, del calcio del fósforo, del potasio y comienza a aumentar francamente la diuresis, siendo dado de alta en buenas condiciones. El objetivo de esta presentación, a propósito de un caso clínico, es revisar la patogenia y tratamientos del síndrome de lisis tumoral


Subject(s)
Humans , Male , Child , Peritoneal Dialysis/methods , Tumor Lysis Syndrome/therapy , Acute Kidney Injury , Dexamethasone , Diuresis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Methotrexate , Tumor Lysis Syndrome/complications , Tumor Lysis Syndrome/diagnosis , Tumor Lysis Syndrome/etiology
20.
Rev. méd. Costa Rica Centroam ; 66(546): 31-3, ene.-mar. 1999. ilus
Article in Spanish | LILACS | ID: lil-257266

ABSTRACT

El Síndrome de Lisis Tumoral es un grupo de disturbios metabólicos asociados a enfermedades malignas que ocurre debido a la lisis celular. El Síndrome se caracteriza por su nefrotoxicidad, la cual lleva al fallo renal agudo, debido principalmente a la hiperfosfatemia y la hiperuricemia. En el artículo se resaltan aspectos sobre la patogénesis de la nefropatía. El diagnóstico se arealiza en presencia del antecedente de uso de quimioterapia en una enfermedad linfoproliferativa asociado a las alteraciones metabólicas típicas (hiperuricemia, hiperfosfatemia, hiperclemia, acidosis láctica e hipoclacemia). El tratamiento se basa principalmente en la hidratación adecuada y la diuresis forzada, junto con otras medidas que detallan en el artículo


Subject(s)
Humans , Tumor Lysis Syndrome/complications , Tumor Lysis Syndrome/diagnosis , Tumor Lysis Syndrome/etiology , Tumor Lysis Syndrome/drug therapy , Tumor Lysis Syndrome/therapy , Costa Rica , Kidney Diseases/diagnosis , Kidney Diseases/therapy
SELECTION OF CITATIONS
SEARCH DETAIL